AW555464 Activators
Chemical activators of centrosomal protein 170B can influence this protein's role in microtubule stabilization and centrosome function through a variety of biochemical pathways. Resveratrol and Metformin, for instance, activate the AMP-activated protein kinase (AMPK) pathway. Activation of this pathway is known to influence microtubule dynamics, which can lead to the enhanced activity of centrosomal protein 170B, as it plays a significant role in microtubule organization. Similarly, agents like Forskolin and Dibutyryl-cAMP elevate cAMP levels, which in turn activate protein kinase A (PKA). PKA can then phosphorylate proteins associated with the centrosome, leading to the activation of centrosomal protein 170B. This phosphorylation enhances the centrosome's ability to nucleate microtubules, a critical aspect of cellular structure and function.
Further, compounds such as Paclitaxel and Vinblastine interact directly with microtubules; Paclitaxel stabilizes them, while Vinblastine disrupts microtubule formation. Both actions can lead to the activation of centrosomal protein 170B as part of the cellular response – either to enhance microtubule stabilization or to compensate for their destabilization. Nocodazole, another microtubule-disrupting agent, also triggers a response that activates centrosomal protein 170B to aid in microtubule reformation. Moreover, Okadaic Acid, by inhibiting protein phosphatases PP1 and PP2A, can lead to increased phosphorylation and subsequent activation of centrosomal protein 170B. Lithium Chloride, through inhibition of GSK-3β, can also activate proteins involved in microtubule stabilization, which may include centrosomal protein 170B. Lastly, molecules like S-Trityl-L-cysteine and BI 2536, which inhibit the mitotic kinesin Eg5 and PLK1 respectively, may lead to the activation of centrosomal protein 170B as the cell compensates for impaired spindle formation or seeks to maintain centrosome integrity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol activates the AMP-activated protein kinase (AMPK) pathway, which in turn can activate centrosomal protein 170B by enhancing its role in microtubule stabilization, as AMPK influences microtubule dynamics. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Metformin activates AMPK, and through AMPK activation, it can enhance the stabilization of microtubules, indirectly causing the activation of centrosomal protein 170B which is involved in microtubule organization. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises cAMP levels, which activates PKA. PKA can phosphorylate proteins associated with the centrosome, potentially leading to the activation of centrosomal protein 170B through phosphorylation-dependent mechanisms. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP, a cAMP analog, activates PKA. Activated PKA can then activate centrosomal protein 170B by phosphorylating associated centrosomal proteins and enhancing centrosome function related to microtubule nucleation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate inhibits phosphodiesterases leading to an increase in cAMP, which activates PKA. Subsequent PKA activation can promote the activation of centrosomal protein 170B through phosphorylation of centrosomal components. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and can enhance the function of centrosomal protein 170B, which is involved in the nucleation and stabilization of microtubules, leading to its activation. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubules, and its application can lead to a cellular response that activates centrosomal protein 170B to compensate for microtubule destabilization and assist in microtubule reformation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid inhibits protein phosphatases PP1 and PP2A, potentially leading to increased phosphorylation of centrosomal proteins and activation of centrosomal protein 170B through enhanced phosphorylation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride inhibits GSK-3β, which can lead to activation of proteins involved in microtubule stabilization, thus potentially activating centrosomal protein 170B as part of the cellular response to stabilizing microtubules. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $100.00 $230.00 $450.00 $1715.00 $2900.00 | 4 | |
Vinblastine disrupts microtubule formation, which can lead to a compensatory activation of centrosomal protein 170B, as it plays a role in microtubule nucleation and stabilization. | ||||||